- Susvimo is under EMA review for nAMD treatment in the EU.
- Contivue with Susvimo showed stable vision outcomes over seven years in the LADDER study.
- The device allows up to two refills per year for continuous delivery.
- Ranibizumab is the active substance in Susvimo.
CE Mark Approval
Roche's Contivue, containing Susvimo, has received the EU CE mark for treating neovascular age-related macular degeneration (nAMD). Susvimo is under review by the European Medicines Agency (EMA) and, once approved, will be the first continuous delivery treatment for nAMD in the EU.
Clinical Study Data
New data from the seven-year LADDER study shows that Contivue with Susvimo provides stable visual outcomes and retinal anatomy over the long term. In the study, 59 patients treated continuously with Contivue with Susvimo maintained best-corrected visual acuity (BCVA) with minimal decline over seven years.
Device Features
Contivue with Susvimo allows for up to two refills per year, offering reliable long-term vision outcomes. The device includes an eye implant for delivering Susvimo and four ancillary devices for filling, inserting, refilling, and removing the implant if needed.
Ranibizumab Formulation
Susvimo contains a customized formulation of ranibizumab, which is gradually released over time. This sustained delivery method aims to provide superior visual outcomes compared to traditional intravitreal injections.
